Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial

By Yahoo! Finance | Nov 1, 2024 at 08:49 AM EST

Biofrontera's Phase III trial for treating superficial basal cell carcinoma with Ameluz gel and PDT showed promising results, meeting primary and secondary endpoints. The stock surged following the positive outcome, with plans to submit the dossier for FDA approval in 2025.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.